Login to Your Account

Vectura, Sosei Bank $7.5M on Start of Phase III COPD Trial

By Donna Young

Tuesday, June 30, 2009
Shares of Vectura Group plc rose 8.5 percent on the London stock exchange Monday after the Chippenham, UK-based firm and its partner, Sosei Group Corp., of Tokyo, said Novartis AG had initiated a Phase III study of NVA237, a dry powder formulation of the muscarinic antagonist glycopyrronium bromide, as an inhalational treatment for chronic obstructive pulmonary disease. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription